Login to Your Account



FDA Panel Comes Out In Favor Of Raptiva From Genentech, XOMA

By Kim Coghill


Wednesday, September 10, 2003
An FDA panel of experts voted in favor of Raptiva, a humanized monoclonal antibody made by Genentech Inc. and XOMA Ltd. for the treatment of moderate to severe plaque psoriasis in adults. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription